waltham

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

3 weeks ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 08, 2025 21:36 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE)…

1 month ago